Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA will open inspection office in China this year

By Pharmaceutical Processing | October 21, 2008

WASHINGTON (AP) _ The FDA will establish its first office in China before the end of the year as part of a broader plan to assure the safety of imports from the developing world. FDA Commissioner Andrew von Eschenbach has laid out a plan to place more than 60 food and drug regulators worldwide over the next year, with a particular focus on India, Latin America and the Middle East. The plan for permanent outposts marks a break from the agency’s current practice of sending inspectors abroad on individual assignments. The safety of imported food and drugs has become a growing concern as domestic manufacturers shift operations overseas and foreign producers make inroads here. Over the past year, the FDA has been criticized for failing to prevent a string of safety problems, including contaminated blood thinners manufactured in China and salmonella-tainted peppers imported from Mexico. “We are sending a very clear message to producers: if you want to have access to our market you need to make products that meet our standards of quality,” Health and Human Services Secretary Michael Leavitt told reporters. Leavitt oversees the FDA and other federal health agencies. FDA officials said the plan would cost about $30 million in its first year, primarily to set up the offices and hire new staffers, including foreign nationals who would report to the agency. Leavitt and von Eschenbach acknowledged that several dozen additional staffers would not be able to visit the thousands of plants across the globe that fall under FDA’s responsibility. They said the U.S. government would need to outsource some inspections to foreign governments and companies, who would verify that plants meet U.S. standards. Officials said the FDA does not have the authority to accredit third-party inspectors and would have to seek Congress’ approval to do so.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE